Biogen (BIIB) PT Lowered to $350 at Oppenheimer
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $212.55 +1.63%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Oppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $350.00 (from $390.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Amgen (AMGN) PT Raised to $400 at Cantor Fitzgerald on Higher Sales Estimates
- Pony AI Inc (PONY) PT Lowered to $17 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
